A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. - Wikidata - awgldk - TriplyDB

A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

http://www.wikidata.org/entity/Q33876638

about

Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical disease Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1 Rational Development of 4-Aminopyridyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51 as Anti-Chagas Agents Expanding the Binding Envelope of CYP51 Inhibitors TargetingTrypanosoma cruziwith 4-Aminopyridyl-Based Sulfonamide Derivatives 4-Aminopyridyl-Based CYP51 Inhibitors as Anti- Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51 Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line Targeting Ergosterol biosynthesis in Leishmania donovani: essentiality of sterol 14 alpha-demethylase New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.Resistance to antifungals that target CYP51.Drug strategies targeting CYP51 in neglected tropical diseases Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.Drug discovery for neglected tropical diseases at the Sandler Center.Interactions of antiparasitic sterols with sterol 14α-demethylase (CYP51) of human pathogens The Effectiveness of Natural Diarylheptanoids against Trypanosoma cruzi: Cytotoxicity, Ultrastructural Alterations and Molecular Modeling Studies Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51)Cathepsin Inhibition Prevents Autophagic Protein Turnover and Downregulates Insulin Growth Factor-1 Receptor-Mediated Signaling in Neuroblastoma Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target.Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens.Advances in Chagas disease drug development: 2009-2010 Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.Therapeutical approaches under investigation for treatment of Chagas disease.Cholesterol metabolism: a potential therapeutic target in Mycobacteria.Chemogenetic Characterization of Inositol Phosphate Metabolic Pathway Reveals Druggable Enzymes for Targeting Kinetoplastid Parasites.Hydroxamic acid derivatives: a promising scaffold for rational compound optimization in Chagas disease.Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.Pharmacokinetics of hydroxymethylnitrofurazone, a promising new prodrug for Chagas' disease treatment CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.Structural design, synthesis and structure-activity relationships of thiazolidinones with enhanced anti-Trypanosoma cruzi activity.Rational Selection of Anti-Microbial Drug Targets: Unique or Conserved?

P2860

Q24597322-6F437AEA-9A57-4EF0-B8D7-E6EE5AAF338D Q27666066-87798B86-BA01-4B3D-9798-31D49F19A966 Q27680103-10014C69-6065-43DF-BE53-12316766A52E Q27683570-CE7A5169-FF1E-4036-B2DC-32279BF2BCA2 Q27684956-0C142038-D53C-4704-A2AD-3C64BC714BC6 Q28481694-5893B373-0B1C-434B-9402-6C564F8E5FD3 Q28543069-C362A179-11A8-4450-9894-B68159F4B581 Q28544037-3BCC814E-6B07-4FA8-8921-B1E1562AB2BF Q30417002-2A2D0C82-F1B9-4403-A53F-57FD1F0B1A5F Q33604028-2A744284-E7F9-4461-9C38-21C93ACA19FC Q33636471-011F0AF3-3950-40AA-8F72-818421524314 Q34276700-ADD7B885-3632-4251-8BC0-1A3289609D7D Q34622554-AA0AE6FF-310D-4272-9AD2-F9E5937E936D Q34701325-28DB293C-DBBA-45DE-A828-5F2648FF7E10 Q35419266-79A6E233-8CFF-4D5A-B227-0A15ED798A4C Q35541487-532BB3C5-4EB9-4658-9B6D-09F1B550E8CD Q36141471-19554F15-4552-411C-948B-12003541F8EA Q36368984-122B8539-A404-4DF8-92D7-8CB99318438E Q36559668-3C5338C0-737C-4C1B-89BC-B9B3B69FE92D Q36594213-3B14EAC5-BEAB-4FDF-A4C6-FE09AFC05540 Q36667070-0A2411D3-F9C2-4ACE-BBD8-75696635095B Q36702159-91849DC7-BBF8-4417-9172-A9B3D8F91E4D Q37449720-18CB8F3E-2EC1-4255-A2A2-B105A58217FB Q38214136-F8675996-9E2E-4FAA-8D47-E5E46CC28727 Q39047211-593F7B18-93D2-4541-B8D0-85D5BC3C6C5A Q40692004-7D3B70C2-424D-4F02-BBA2-7B33EDF64D4C Q41022118-AB4B5ACA-5A68-4D22-BC8F-555347434531 Q41955446-BFC3A86F-B2E3-404B-9080-1BC4C823362C Q42098034-2742E776-0D16-41AE-9980-54509BC2FF1E Q47239192-A52D27AD-F0B0-4259-BCF2-4BCEB02F6292 Q48342608-79D2A8B4-7F1D-4AEC-94C5-2A2D70BCE56F Q54644826-9231B586-A3B7-4BE5-8B97-08E50A96C6F3 Q58850854-DC1321F0-CA06-4B52-8F42-DF0FC6320FE6

P2860

A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

http://www.wikidata.org/entity/Q33876638

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

@ast

A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

@en

type

label

A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

@ast

A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

@en

prefLabel

A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

@ast

A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

@en

P1433

Q33876638-7D8699AC-A92F-4FEF-BF46-8BB9802D50DC

P1476

Q33876638-90326801-8B2B-45D2-86B2-8963F049959E

P2093

Q33876638-1AB0E312-E1DC-4CC9-AA9A-A0421DDBA372

Q33876638-4E2827F2-AB3D-4783-B16E-4A3931B910DD

Q33876638-5061FE46-9625-485B-9CDB-24167588B13F

Q33876638-77F3717D-4FD8-43B4-94DC-540566EAED5A

Q33876638-B87D461D-160C-4EF5-B08B-552CB6E4E227

Q33876638-D67BE036-2FCA-4A1D-BFFD-6899DBFA64E1

Q33876638-DE0713B4-0F8D-449C-A4BF-7B26879E60FB

P2860

Q33876638-0100E6A5-F31A-453B-B25A-A5FEC4DEA3CF

Q33876638-0DD120D3-ADD7-47B2-BF86-C84B1EC969BB

Q33876638-13C0C2B7-6186-487D-8612-A4D5F5109F17

Q33876638-1ABE3B2B-FFD1-43A6-A437-D11A0E80507C

Q33876638-20130E9C-1377-4055-8202-97C7FD62FA8F

Q33876638-245FA012-E531-4D5C-A1ED-06582CB16AEA

Q33876638-2E0B58C3-773F-45C2-B48D-E85A660AAC7E

Q33876638-32DBF671-BA6B-4738-8586-E504572B3A0D

Q33876638-36FEFD47-3F29-4B0E-BB6A-CC766F4F37AA

Q33876638-3B633309-3399-4D20-9A4B-195C58C3A9AB

P304

Q33876638-D02929F4-0DE3-4FEC-9464-41061ACB4048

P31

Q33876638-C4226484-8610-4CF7-8B23-C4255A6AD377

P356

Q33876638-B5A59B9B-0068-46B2-AB4A-B29C7AF1C295

P407

Q33876638-898E55FA-40E8-49CA-8DD2-265B947E4280

P433

Q33876638-7D1E7D76-3B86-4D37-A2B1-6E37E651D895

P478

Q33876638-432D4FB0-608C-4446-A73D-B710B7385F7C

P50

Q33876638-10096CBD-072C-4A0A-9649-A437902C6B8C

Q33876638-2F0F0105-F4FD-4557-9EFB-02CBC8A23631

P577

Q33876638-7771D71B-DDC5-47F4-8706-D24DD953BD38

P5875

Q33876638-44D32421-B30A-4736-A733-8F8D74FE591B

P698

Q33876638-B5B3C0F7-8CE9-4F65-B77F-21B8DFC1C1D4

P921

Q33876638-BB2AC4C7-DDDB-4459-A0B5-4F778E7BAE9F

P932

Q33876638-5477BFC2-C737-4FFC-91E8-850C0C66471C

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

@en

P2093

Chiung-Kuang Chen

http://www.w3.org/2001/XMLSchema#string

Jonathan B Johnston

http://www.w3.org/2001/XMLSchema#string

Juan C Engel

http://www.w3.org/2001/XMLSchema#string

Larissa M Podust

http://www.w3.org/2001/XMLSchema#string

Patricia S Doyle

http://www.w3.org/2001/XMLSchema#string

Siegfried S F Leung

http://www.w3.org/2001/XMLSchema#string

Stephanie D Hopkins

http://www.w3.org/2001/XMLSchema#string

P2860

Induction of resistance to azole drugs in Trypanosoma cruzi.

Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection

A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection

Small-Molecule Scaffolds for CYP51 Inhibitors Identified by High-Throughput Screening and Defined by X-Ray Crystallography

Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit

Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy

Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes

P304

2480-2488

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00281-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Matthew P. Jacobson

James H McKerrow

P577

2010-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43131060

http://www.w3.org/2001/XMLSchema#string

P698

20385875

http://www.w3.org/2001/XMLSchema#string

P921

P932

2876414

http://www.w3.org/2001/XMLSchema#string